Genetic Technologies Limited Revenue Growth Rates (GENE), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Genetic Technologies Limited  (GENE)
 

GENE's Revenue Growth by Quarter and Year

Genetic Technologies Limited's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GENE Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 7.66
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 7.66

GENEs Annual Revenue
Genetic Technologies Limited's Revenue in the fiscal year 2024 $ 7.66 millions
Genetic Technologies Limited's Revenue in the fiscal year 2023 $ 5.85 millions
Genetic Technologies Limited's Revenue in the fiscal year 2022 $ 4.93 millions
Genetic Technologies Limited's Revenue in the fiscal year 2021 $ 0.09 millions
Genetic Technologies Limited's Revenue in the fiscal year 2020 $ 6.62 millions




GENE Revenue fourth quarter 2024 Y/Y Growth Comment
Genetic Technologies Limited achieved in the fourth quarter 2024, above Company average Revenue surge of 25449.28% year on year, to $ 7.66 millions.

Looking into fourth quarter 2024 results within Biotechnology & Pharmaceuticals industry 56 other companies have achieved higher Revenue growth. While Genetic Technologies Limited' s Revenue doubling of 25449.28% ranks overall at the positon no. 3615 in the fourth quarter 2024.


GENE Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December 25449.28 % -84.21 % - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   25449.28 % -84.21 % - -

Financial Statements
Genetic Technologies Limited's fourth quarter 2024 Revenue $ 7.66 millions GENE's Income Statement
Genetic Technologies Limited's fourth quarter 2023 Revenue $ 0.03 millions Quarterly GENE's Income Statement


GENE Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   25449.28 % -84.21 % - -


Back to GENE Growth rate Comparisons >> Back to GENE Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #57
Healthcare Sector #530
Overall #3615

Revenue Y/Y Growth Statistics
High Average Low
-86.56 % -86.56 % -86.56 %
(Jun 30 2019)  
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #57
Healthcare Sector #530
Overall #3615
Revenue Y/Y Growth Statistics
High Average Low
-86.56 % -86.56 % -86.56 %
(Jun 30 2019)  

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Genetic Technologies Limited's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GENE's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GENE's IV. Quarter Q/Q Revenue Comment


Genetic Technologies Limited's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Jun 30 2020)
Cumulative Revenue 12 Months Ending $ 7.66 $ 5.85 $ 4.93 $ 0.09 $ 6.62
Y / Y Revenue Growth (TTM) 31.09 % 18.59 % 5373.9 % -98.64 % 25914.94 %
Year on Year Revenue Growth Overall Ranking # 3615 # 3594 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 31.09 % 18.59 % 5373.9 % -98.64 % 25914.94 %
Seq. Revenue Growth (TTM) Overall Ranking # 3615 # 3674 # 0 # 0 # 0


Cumulative Revenue growth Comment
Genetic Technologies Limited saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 31.09% year on year, to $ 8 millions if the fiscal year would have ended in Jun 30 2024.
Genetic Technologies Limited's trailing twelve months Revenue growth was higher than company's average -86.56% and higher than 18.59% growth in Jun 30 2023.

In the Healthcare sector 529 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3594 to 3615.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 57
Healthcare Sector # 530
Overall # 3615

Revenue TTM Y/Y Growth Statistics
High Average Low
-86.56 %
 -86.56 %
-86.56 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 57
Sector # 530
S&P 500 # 3615
Cumulative Revenue growth Comment
Genetic Technologies Limited saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 31.09% year on year, to $ 8 millions if the fiscal year would have ended in Jun 30 2024.
Genetic Technologies Limited's trailing twelve months Revenue growth was higher than company's average -86.56% and higher than 18.59% growth in Jun 30 2023.
The momentum is even more impressive from twelve months ended Jun 30 2023 exhibited at 31.09 % increase from $5.85 millions in the period from Jun 30 2023 to Jun 30 2020.

In the Healthcare sector 529 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3594 to 3615.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 57
Healthcare Sector # 530
Overall # 3615

Revenue TTM Y/Y Growth Statistics
High Average Low
-86.56 %
-86.56 %
-86.56 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 57
Sector # 530
S&P 500 # 3615




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GENE's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________16,997.50%$ 16,997.495 millions
Iovance Biotherapeutics inc 15,189.21%$ 15,189.212 millions


About Genetic Technologies Limited Revenue Growth Rates (GENE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Genetic Technologies Ltd (CIK 1166272).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-24-038693
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Genetic Technologies Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.